Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Walaa A. Alshahrani"'
Autor:
Yazed Saleh Alsowaida, Khalid Al Sulaiman, Ahmad J. Mahrous, Aisha Alharbi, Nisrin Bifari, Walaa A. Alshahrani, Thamer A. Almangour, Nader Damfu, Aseel A. Banamah, Raghad R. Abu Raya, Raghad A. Sadawi, Arwa Alharbi, Ahmed Alsolami, Yahya Essa, Alaa Ghaze Almagthali, Shahad F. Alhejaili, Wed A. Qawwas, Ghaida Salamah Alharbi, Atheer Suleiman Alkeraidees, Afnan Alshomrani, Manal A. Aljohani, Ohoud Aljuhani
Publikováno v:
International Journal of Infectious Diseases, Vol 148, Iss , Pp 107234- (2024)
Objectives: To evaluate the clinical outcomes of anidulafungin for candidemia treatment in critically ill patients with obesity. Methods: A multicenter, retrospective cohort study was conducted in Saudi Arabia for critically ill adults with candidemi
Externí odkaz:
https://doaj.org/article/61c42b3ea68d496ba16783183ab94eba
Autor:
Khalid Al Sulaiman, Ohoud Aljuhani, Hadeel Alkofide, Manal A. Aljohani, Hisham A. Badreldin, Mahasen Al Harbi, Ghalia Aquil, Raghad Alhajaji, Rahaf A. Alqahtani, Alaa Babonji, Maha Altuwayr, Asma A. Alshehri, Mashael Alfaifi, Abdullah F. Alharthi, Mohammed Alzahrani, Tareq Al Sulaiman, Nasser Alqahtani, Walaa A. Alshahrani, Abdulmalik Al Katheri, Abdulkareem M. Albekairy
Publikováno v:
Thrombosis Journal, Vol 22, Iss 1, Pp 1-8 (2024)
Abstract Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently investigating the use of Apixaban in underweight patients, w
Externí odkaz:
https://doaj.org/article/9ac2be0a56af4c21acf8807ea553890d
Autor:
Abdulaali R. Almutairi, Walaa A. Alshahrani, Ghaida K. Alhathlol, Fatimah Alsheikh, Abdulaziz Alakeel, Majed S. Al Yami, Mohammad Fouda, Omar A. Almohammed, Meshal S. Alhamed, Awatif Hafiz, Hussam Kutbi, Alaa Bagalagel, Aisha Alharbi, Mashael Alaboud, Sarah Aljohani, Waddah Ashram
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 12, Pp 102203- (2024)
Introduction: Evolocumab’s short-term efficacy and safety were proven in phase-3 clinical trial, but its long-term safety and effectiveness in the Saudi population are yet to be studied. The aim of this study was to assess the long-term safety and
Externí odkaz:
https://doaj.org/article/f13343917f36432888fdeb2e6d6bb801